Quark Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Quark Pharmaceuticals, Inc.
Who wants to go public during a once-in-a-century crisis? It seems like quite a few medtechs do.
The companies will launch "precision medicine strategies" for chronic disease that use Renalytix' AI-enabled IVDs.
The Mount Sinai spin-off believes its KindeyIntelX system can identify COVID-19 patients at high risk for long-term kidney damage.
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.
- Antisense, Oligonucleotides
- Large Molecule